Categories AlphaGraphs, Earnings, Health Care

MEDS Earnings: Highlights of Trxade Health’s Q2 2023 financial results

Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decrease in revenues for the second quarter of fiscal 2023. The company’s net loss widened from the prior-year quarter.

Trxade Q2 2023 earnings infographic

Revenues decreased 31% from last year to $2.25 million in the second quarter. The decline mainly reflects weak performance by the Integra subsidiary.

Net loss attributable to Trxade Health was $1.97 million or $2.90 per share in Q2, compared to a loss of $1.08 million or $1.99 per share in the same period of last year.

The TRxADE platform increased its registered users by 1,149 or 8% as of June 30, 2023, compared to June 30, 2022. For the six months ended June 30, new registrations were 291, compared to 339 a year earlier. At the end of the quarter, the company had total registered users of around 4,100+, compared to 12,962 last year.

Prior Performance

  • Trxade Q3 2022 earnings infographic
  • Trxade Q2 2022 earnings infographic

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top